An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant in HIV-HCV infected patients Studio in aperto per valutare l'efficacia clinica di sofosbuvir, somministrato in associazione a ribavirina in fase pre-trapianto, nel prevenire recidive post-trapianto dell'infezione da virus dell'epatite C (HCV) in soggetti con infezione HIV-HCV.

Trial Profile

An Open-Label Study to Explore the Clinical Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant in HIV-HCV infected patients Studio in aperto per valutare l'efficacia clinica di sofosbuvir, somministrato in associazione a ribavirina in fase pre-trapianto, nel prevenire recidive post-trapianto dell'infezione da virus dell'epatite C (HCV) in soggetti con infezione HIV-HCV.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2014

At a glance

  • Drugs Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms SOFT-preOLT
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 07 Sep 2014 Planned End Date changed to 25 Nov 2016.
    • 07 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top